『Pharmacology News』のカバーアート

Pharmacology News

Pharmacology News

著者： Circle Of Insight Productions
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 Join Dr. Carlos on “Pharmacology Insights,” your source for the latest research and news on pharmacology, medications, and street drugs. Each episode delves into cutting-edge discoveries, practical applications, and the evolving landscape of both legal and illicit substances. Gain a deeper understanding of how drugs work, their impacts on health, and the latest trends in medication and drug use. Tune in for expert analysis and insightful discussions that keep you informed on all things pharmacological.Copyright Circle Of Insight Productions 社会科学 科学 経済学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Ibogaine: Miracle Cure or Medical Gamble? The Truth Behind a Controversial Psychedelic

    Ibogaine: Miracle Cure or Medical Gamble? The Truth Behind a Controversial Psychedelic
    2026/04/20
    This episode explores ibogaine as a controversial psychedelic treatment for addiction, examining its reported effects on opioid withdrawal, cravings, and psychological insight alongside serious cardiac and neurological risks. It provides a balanced, evidence-based analysis of ibogaine research, including limitations such as lack of randomized trials, selection bias, and short-term outcome data. Ideal for listeners interested in addiction science, mental health innovation, neuroscience, and the risks and promise of emerging psychedelic therapies.
    続きを読む 一部表示
    7 分
  • Low-Dose Methamphetamine Neuroprotection: What the Studies Actually Show

    Low-Dose Methamphetamine Neuroprotection: What the Studies Actually Show
    2026/04/20
    3 分
  • The Messy Truth About Antidepressants: Benefits, Risks, and the Limits of the Evidence

    The Messy Truth About Antidepressants: Benefits, Risks, and the Limits of the Evidence
    2026/04/19
    Antidepressants demonstrate modest but real benefits for moderate-to-severe depression, with large meta-analyses showing consistent advantages over placebo and meaningful improvements in function for many patients, yet these gains are often smaller than portrayed and heavily influenced by high placebo responses.
The evidence base comes with important limitations, including publication bias, short trial durations, industry influence, and challenges in blinding, which can inflate perceived efficacy while understating long-term risks such as sexual dysfunction, emotional blunting, and weight gain reported more frequently in real-world surveys.
Navigating antidepressants requires pragmatic humility: they are a valuable tool for the right person at the right time when used with careful monitoring, deprescribing when appropriate, and combined with therapy and lifestyle changes, rather than as a one-size-fits-all solution or something to fear outright.
    続きを読む 一部表示
    9 分
まだレビューはありません